Elicera Therapeutics AB Logo

Elicera Therapeutics AB

Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.

ELIC | ST

Overview

Corporate Details

ISIN(s):
SE0015382080 (+1 more)
LEI:
549300I35L0R4INBFG27
Country:
Sweden
Address:
C/O Elicera Therapeutics AB, 402 24 Göteborg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Elicera Therapeutics AB is a clinical-stage immuno-oncology company that develops cell and gene therapies for immune-based cancer treatments. The company's work focuses on two core technology areas: oncolytic viruses and Chimeric Antigen Receptor (CAR) T-cell therapies. Elicera's key asset is the proprietary iTANK (Immuno-Oncology Targeting and Killing) technology platform, a universal solution designed to enhance the efficacy of any CAR T-cell therapy by enabling a multi-targeted immune attack, particularly against solid tumors. The company's pipeline includes four drug candidates, with its oncolytic virus (ELC-100) and CAR T-cell therapy (ELC-301) in or entering clinical phase I/II trials for neuroendocrine tumors and B-cell lymphoma, respectively.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Elicera Therapeutics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Elicera Therapeutics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Margareth Jorvid Other Other 21,700 40,145.00 SEK

Peer Companies

Company Country Ticker View
VENTURE LIFE GROUP PLC Logo
Develops, manufactures, and distributes consumer self-care products and medical devices globally.
United Kingdom VLG
Vetoquinol SA Logo
Develops and markets veterinary drugs and products for companion animals and livestock worldwide.
France VETO
Vifor Pharma AG Logo
A global leader in specialty pharmaceuticals for iron deficiency and nephrology.
Switzerland VIFN
ViGenCell Inc. Logo
Developing T-cell immune therapies to treat cancer and other incurable diseases.
South Korea 308080
Virbac Logo
Develops animal health pharma, vaccines & diagnostics for vets, farmers & pet owners globally.
France FR000
ViroGates A/S Logo
Develops suPAR diagnostic tests for inflammation risk assessment in acute care and longevity.
Denmark VIRO
Vistin Pharma Logo
A leading global producer of Metformin Hydrochloride for the global healthcare market.
Norway VISTN
Vita 34 AG Logo
A cell bank storing umbilical cord stem cells as biological insurance for families' future health.
Germany V3V
Vivoryon Therapeutics N.V. Logo
Developing first-in-class small molecule therapies for age-related and kidney diseases.
Germany VVY
Develops innovative, non-narcotic drugs for pain and central nervous system (CNS) diseases.
South Korea 082800

Talk to a Data Expert

Have a question? We'll get back to you promptly.